{"title":"Research progress of conditioning regimens in chimeric antigen receptor modified T cells immunotherapy","authors":"Yujie Wang, Tao Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2020.01.014","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor modified T cells (CAR-T) therapy plays a key role in the treatment of relapsed/refractory hematological malignancies. And the efficacy of such promising therapy is influenced by many factors, including the production, expansion and lethality of CAR-T cells, the kinds and status of diseases, as well as conditioning regimens. Conditioning regimens such as lymphodepleting prior to CAR-T cells infusion are one of good help to enhance the efficacy of CAR-T therapy. Chemothrapy with cyclophosphamide, fludarabine, pentostatin, bendamustine and cytarabine, as well as total body irradiation (TBI) are main conditioning regimens of CAR-T therapy. However, the optimal selection of conditioning regimens, the optimal dose are still uncertain. This article reviews the current status and research progress of conditioning regimens in CAR-T therapy, in order to find the best scheme and improve the efficacy of CAR-T therapy. \n \n \nKey words: \nHematologic neoplasms; Transplantation conditioning; T-lymphocytes; Radiotherapy; Chimeric antigen receptor modified T cells","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2020.01.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Chimeric antigen receptor modified T cells (CAR-T) therapy plays a key role in the treatment of relapsed/refractory hematological malignancies. And the efficacy of such promising therapy is influenced by many factors, including the production, expansion and lethality of CAR-T cells, the kinds and status of diseases, as well as conditioning regimens. Conditioning regimens such as lymphodepleting prior to CAR-T cells infusion are one of good help to enhance the efficacy of CAR-T therapy. Chemothrapy with cyclophosphamide, fludarabine, pentostatin, bendamustine and cytarabine, as well as total body irradiation (TBI) are main conditioning regimens of CAR-T therapy. However, the optimal selection of conditioning regimens, the optimal dose are still uncertain. This article reviews the current status and research progress of conditioning regimens in CAR-T therapy, in order to find the best scheme and improve the efficacy of CAR-T therapy.
Key words:
Hematologic neoplasms; Transplantation conditioning; T-lymphocytes; Radiotherapy; Chimeric antigen receptor modified T cells
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
